Bicara Therapeutics (BCAX) Stock: Buy, Sell, or Hold?
BCAX - Bicara Therapeutics Inc. Common Stock
$22.81
-0.29 (-1.26%)
▼
5d:
-2.27%
30d:
-7.39%
90d:
+7.19%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When BCAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BCAX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BCAX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCAX is currently trading at $22.81, which is considered oversold relative to its 30-day fair value range of $23.06 to $25.87.
Technical Outlook: Technically, BCAX is in a uptrend. The price is currently testing key support at $22.26. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BCAX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.54 (+51.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCAX is in a uptrend. The price is currently testing key support at $22.26. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BCAX scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.54 (+51.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$23.06 -
$25.87
Company Quality Score
51/100
(HOLD)
Options IV Signal
31th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 31th percentile)
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.4% below Wall St target ($34.54)
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$23.06 -
$25.87
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.77
(16.5%)
Support & Resistance Levels
Support Level
$22.26
Resistance Level
$24.59
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.58
Wall Street Target
$34.54
(+51.4%)
Share & Embed Analysis
Last updated: September 13, 2026 8:53 AM ET
Data refreshes hourly during market hours. Next update: 9:53 AM
Data refreshes hourly during market hours. Next update: 9:53 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Ivan Hyep
SELL
9200 shares
2026-04-21
Claire Mazumdar
SELL
15000 shares
2026-04-20
Ryan Cohlhepp
SELL
12500 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
